|
Patent landscape, scope, and claims: |
Overview of U.S. Patent 6,310,094
United States Patent 6,310,094, issued on October 30, 2001, to Merck & Co. Inc., covers a pharmaceutical composition and method of treatment involving a controlled-release formulation of the HIV protease inhibitor, amprenavir. The patent claims focus on the specific composition, novel formulations, and dosing regimens designed to optimize pharmacokinetics and patient adherence.
What Is the Scope and What Do the Claims Cover?
Claims Breakdown
The patent contains 25 claims, with core coverage centered on:
-
Claim 1: A controlled-release pharmaceutical composition comprising an effective amount of amprenavir or its salts in a matrix capable of releasing the active ingredient over an extended period, specifically 8-24 hours.
-
Claims 2-10: Variations involving specific polymeric matrix materials, such as polyvinyl acetate, ethylcellulose, or combinations thereof, designed to modulate release profiles.
-
Claims 11-15: Dosing methods and administration schedules, including once-daily or twice-daily regimens for HIV therapy.
-
Claims 16-25: Formulation specifics such as particle size, and optional inclusion of pharmaceutically acceptable carriers or excipients; also claims on a method of manufacturing the controlled-release composition.
Scope Analysis
-
The core invention pertains to controlled-release formulations of amprenavir, focusing on specific matrix materials and dosing schedules intended to reduce pill burden and improve pharmacokinetic consistency.
-
The claims are primarily product-by-process, emphasizing composition and method of production within defined release parameters.
-
The patent explicitly claims extended-release matrices differing from standard immediate-release formulations, with a focus on sustained plasma levels for HIV management.
Potentially Overlapping Patents
-
Related patents include WO 97/20984, which describes similar polymers for controlled-release formulations of protease inhibitors.
-
The scope of 6,310,094 overlaps with subsequent patents covering formulations of other protease inhibitors (e.g., atazanavir, darunavir) and their controlled-release systems.
Patent Landscape and Competitive Space
Key Patent Families and Related Patents
| Patent Number |
Issue Date |
Assignee |
Focus |
Status/Notes |
| US 6,310,094 |
2001 |
Merck |
Amprenavir controlled release |
Expired 2018-2019, now in public domain |
| US 6,586,531 |
2003 |
Merck |
Further formulations, dosage regimens |
Expired 2023 |
| WO 97/20984 |
1997 |
Merck |
Polymer matrices for protease inhibitors |
Family of prior art |
| US 9,123,636 |
2015 |
Gilead |
Other protease inhibitor formulations |
Active patent |
Market Context
-
The patent landscape for HIV protease inhibitors includes a mixture of composition patents, method patents, and formulation-specific patents.
-
Merck's focus on controlled-release formulations aimed at extending dosing intervals (e.g., once daily), corresponding to regulatory filings around 2000-2003 for amprenavir (marketed as Agenerase).
-
Post-expiration, generic manufacturers include Teva, Mylan, and Aurobindo, which have filed Abbreviated New Drug Applications (ANDAs) referencing these patents.
Regulatory and Litigation Activity
-
The patent was referenced in multiple ANDA filings, leading to patent challenge proceedings under the Hatch-Waxman Act.
-
Patent expiration occurred as planned, with generic entry becoming possible after 2018, based on patent term adjustments and orange book listings.
Implications for R&D and Investment
-
The expiration of the 6,310,094 patent broadened access to amprenavir formulations but also spurred growth in generics.
-
Subsequent drug development shifted focus to newer protease inhibitors with longer half-lives and better safety profiles, such as atazanavir and darunavir, which built upon the prior art landscape.
-
Companies continue to innovate on controlled-release platforms for antiretrovirals, leveraging formulations for improved compliance and reduced dosing frequency.
Key Takeaways
-
U.S. Patent 6,310,094 covers a controlled-release composition of amprenavir with claims on specific polymer matrices and dosing methods, relevant from 2001 until expiry around 2018-2019.
-
Its scope centers on extended-release formulations designed to improve pharmacokinetics and adherence for HIV therapy.
-
The patent landscape includes related composition, process, and method patents, with Merck as the primary inventor.
-
Expiration facilitated generic development, though innovator activity shifted towards next-generation protease inhibitors.
-
Current patent protections in the space focus on newer formulations and delivery systems for antiretroviral agents.
FAQs
1. Are the claims of U.S. Patent 6,310,094 broad enough to cover all controlled-release formulations of amprenavir?
No. The claims specify particular matrices and methods, limiting scope. They do not cover all formulations, especially after expiration. Generics can pursue bioequivalent options not infringing specific claims.
2. What is the significance of the patent’s expiration for the market?
It allowed generic manufacturers to produce amprenavir formulations, increasing competition, lowering prices, and expanding access.
3. How does this patent relate to current HIV drug formulations?
It laid groundwork for controlled-release strategies; however, newer drugs with longer half-lives have supplanted amprenavir’s formulations.
4. Are there continuation patents or related filings that extend the patent estate beyond 2018?
No active continuation patents extend beyond the original expiry; later patents focus on different compounds or delivery systems.
5. Can companies develop new controlled-release HIV drugs based on the principles in this patent?
Yes, but they must avoid infringing the claims or wait for patent expiration. They can also innovate on different APIs or delivery mechanisms outside the scope.
References
- USPTO Patent Database. U.S. Patent 6,310,094.
- FDA Orange Book. Amprenavir listings and patents.
- Merck & Co. Public disclosures and filings.
- PatentScope. WO 97/20984.
- M. Andersson et al., "Controlled release formulations of protease inhibitors," J Pharm Sci, 2002.
More… ↓
⤷ Start Trial
|
